ASTIC Autologous Stem Cell Transplantation for Crohn’s Disease

Overview

Transplant study for patients with relapsing Crohn's disease demonstrating clear intolerance or toxicity to conventional treatment. The purpose of this study is to determine whether there is a potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice.

Full Title of Study: “Autologous Stem Cell Transplantation for Crohn’s Disease: ASTIC”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2013

Detailed Description

Open label, phase III, randomised, multicentre study comparing early transplantation procedure with transplantation carried out to the same protocol but delayed by one year. The status of patients undergoing early HSCT will be evaluated after one year and compared to those about to undergo delayed HSCT Patients will be randomised to: – Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation – Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.

Interventions

  • Procedure: Autologous haematopoietic stem cell transplant
    • All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.

Arms, Groups and Cohorts

  • Experimental: Transplant Arm
    • Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
  • Experimental: Delayed Transplant
    • Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation

Clinical Trial Outcome Measures

Primary Measures

  • Proportion patients in sustained disease remission
    • Time Frame: 1 year
    • To evaluate the potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn’ s disease.

Secondary Measures

  • patients who have not responded to immunosuppressant medication
    • Time Frame: 1 – 2 years
    • To evaluate the safety of Hematopoietic Stem Cell Transplantation (HSCT) in Crohn’s disease patients who have not responded to immunosuppressant medication

Participating in This Clinical Trial

Inclusion Criteria

Inclusion criteria:

mandatory 1. Age between 18 and 50 years (Patients aged 50-65 can participate if specially approved by the Trial Steering Committee) 2. Confirmed diagnosis of active Crohn's Disease 3. Unsatisfactory course despite 3 immunosuppressive agents (usually azathioprine, methotrexate and infliximab) in addition to corticosteroids. Patients should have relapsing disease (i.e. >1 exacerbation/year) despite thiopurines, methotrexate and/or infliximab maintenance therapy or clear demonstration of intolerance / toxicity to these drugs. 4. Impaired function and quality of life, compared to population means, on at least one of the following: 1. IBDQ (Appendix 6) 2. European Questionnaire of Life quality (EuroQOL-5D, Appendix 4) 3. Impaired function on Karnofsky index (Appendix 7) 5. Current problems unsuitable for surgery and patient at risk for developing short bowel syndrome. 6. Informed consent Inclusion criteria:

discretionary 1. Wherever possible, diseased tissue should be accessible endoscopically for objective histological study but in the case of small bowel disease that is extensive but does not extend to duodenum or terminal ileum, participation without endoscopy is allowed. 2. Smokers may enter the study provided they have received intensive counselling about smoking. 3. Add patients with ileostomy/colostomy and patients with short bowel syndrome Exclusion Criteria:

1. Pregnancy or unwillingness to use adequate contraception during the study 2. Concomitant severe disease 3. Diarrhoea due to short small or large bowel 4. Infection or risk thereof 5. Significant malnutrition: Body Mass Index (BMI) ≤18, serum albumin <20 g/l 6. Previous poor compliance 7. Concurrent enrolment in any other protocol using an investigational drug or hematopoietic growth factor up to four weeks before study entry. 8. Lack of funding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Society for Blood and Marrow Transplantation
  • Collaborator
    • The Broad Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Christopher J Hawkey, Study Chair, Nottingham University Hospital – Wolfson Digestive Diseases Centre

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.